Granted Patent
B2
US 7,442,536 · App. 11/759,954 · Granted Oct 28, 2008
Cysteinized ribonuclease and targeting moiety conjugated thereto
Assignee:
Alfacell Corporation
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A cysteinized variant of an RNase disclosed in U.S. Pat. No. 6,239,257 B1 is disclosed. A targeting moiety can be conjugated to the cysteine residue.
Claims (3)
1. An isolated protein having the amino acid sequence of SEQ ID NO: 69.
2. A conjugate protein comprising the protein of claim 1 and a targeting moiety conjugated to the cysteine residue at position 71.
3. An isolated protein having the amino acid sequence of SEQ ID NO: 55.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 10, 2020
From: TAMIR BIOTECHNOLOGY, INC.
To: ORGENESIS INC.
Reel/Frame 052892/0702 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 27, 2020
From: SAXENA, SHAILENDRA K.
To: ALFACELL CORPORATION
Reel/Frame 052241/0958 →
CHANGE OF NAME
Recorded Mar 27, 2020
From: ALFACELL CORPORATION
To: TAMIR BIOTECHNOLOGY, INC.
Reel/Frame 052251/0288 →
Continuity (2)